Brain-to-blood transporters for endogenous substrates and xenobiotics at the blood-brain barrier: an overview of biology and methodology.
In the past decade, research into P-glycoprotein involving the blood-brain barrier (BBB) has seen a shift in the concept of the BBB as a structural barrier to that of a functional barrier for xenobiotics and changed simultaneously the strategy for the discovery and development of drugs acting in the CNS. As far as making advances in neurotherapeutics are concerned, the brain-to-blood transport function at the BBB will be one of the most important issues. Knowing the limitations of the in vivo and in vitro methods for BBB efflux research, it is essential to adopt a multidisciplinary approach in investigating the true physiological role of the BBB. Among several methods, the Brain Efflux Index method and the use of conditionally immortalized brain capillary endothelial cell lines, established from transgenic rats harboring temperature-sensitive simian virus 40 large T-antigen gene, are likely to be very useful tools for the BBB efflux transport research. According to our recent findings using these methods, several transporters in the brain capillary endothelial cells appear to play an important role in reducing the brain level of hydrophilic endogenous substrates produced either in the brain or peripheral organs, e.g., neurotransmitters, neuromodulators, metabolites of neurotransmitters, and uremic toxins. It has been reported also that large hydrophilic molecules, such as IgG, apo-transferrin, and amyloid-beta peptide, are susceptible to brain-to-blood efflux transport. In the light of the latest findings, we have formed the hypothesis that the BBB acts as a CNS detoxifying system for both endogenous substrates and xenobiotics in the brain. A fuller understanding of the physiological role of BBB efflux transporters will provide rational insights to assist in the development of safer neurotherapeutics.
Terasaki
Tetsuya
T
New Industry Creation Hatchery Center and Graduate School of Pharmaceutical Sciences, Tohoku University, Aoba, Aramaki, Aoba-ku, Sendai 980-8578, Japan. terasaki@mail.pharm.tohoku.ac.jp
Ohtsuki
Sumio
S
D000818:Animals; D001812:Blood-Brain Barrier / Q000502:physiology*; D002352:Carrier Proteins / Q000378:metabolism* / Q000502:physiology; D006801:Humans; D014118:Toxins, Biological / Q000378:metabolism; D015262:Xenobiotics / Q000378:metabolism*
D002352:Carrier Proteins; D014118:Toxins, Biological; D015262:Xenobiotics
J Infect Dis. 1988 Sep;158(3):630-2
2842410
J Neurochem. 2003 Nov;87(4):891-901
14622120
Kidney Int. 2004 Jan;65(1):162-74
14675047
Brain Res. 2000 Sep 8;876(1-2):148-53
10973603
J Pharm Pharmacol. 1987 Sep;39(9):705-10
2445948
J Neuropathol Exp Neurol. 1971 Jan;30(1):137-8
5542523
Adv Drug Deliv Rev. 1999 Apr 5;36(2-3):195-209
10837716
Cancer Res. 2004 May 1;64(9):3296-301
15126373
Clin Chim Acta. 1965 Nov;12(5):551-4
5865891
Life Sci. 2000 Oct 20;67(22):2699-711
11105986
Mol Pharmacol. 2002 Jun;61(6):1289-96
12021389
J Pharmacol Exp Ther. 2001 Mar;296(3):723-35
11181899
Int J Cancer. 2002 Feb 10;97(5):626-30
11807788
J Clin Invest. 2000 Dec;106(12):1489-99
11120756
J Neurochem. 2004 Apr;89(2):503-13
15056293
J Biol Chem. 1999 Nov 5;274(45):31891-5
10542215
Science. 1978 Oct 13;202(4364):225-7
211586
Nat Med. 2000 Aug;6(8):916-9
10932230
Acta Physiol Scand. 1980 Mar;108(3):223-9
6103638
Drug Discov Today. 2003 Oct 15;8(20):944-54
14554158
J Neurochem. 2000 Nov;75(5):1907-16
11032880
J Neuroimmunol. 2001 Mar 1;114(1-2):168-72
11240028
J Pharmacol Exp Ther. 2004 Nov;311(2):449-55
15218051
J Neurochem. 2001 Mar;76(5):1597-600
11238745
J Pharmacol Exp Ther. 1996 Jun;277(3):1550-9
8667222
J Neurochem. 2001 Feb;76(4):1121-8
11181832
Life Sci. 1992;51(18):1427-37
1357522
Neuroreport. 2002 Nov 15;13(16):2059-63
12438926
Proc Natl Acad Sci U S A. 1989 Jan;86(2):695-8
2563168
AAPS PharmSci. 2000;2(3):E27
11741243
Pharmacogenetics. 2002 Oct;12(7):535-41
12360104
J Cereb Blood Flow Metab. 2001 Oct;21(10):1232-9
11598501
J Drug Target. 2000;8(6):357-70
11328662
J Neurochem. 2004 Aug;90(4):931-41
15287899
Life Sci. 2000;66(7):649-62
10794520
J Cell Biol. 1967 Jul;34(1):207-17
6033532
J Neurochem. 1992 Apr;58(4):1499-503
1372345
J Neurochem. 1999 May;72(5):2135-44
10217295
Neurosci Res. 2002 Oct;44(2):173-80
12354632
J Pharmacol Exp Ther. 1997 Apr;281(1):369-75
9103519
J Biol Chem. 1995 Jun 23;270(25):14913-8
7797470
Pharm Res. 2003 Sep;20(9):1394-400
14567633
Pharm Res. 2000 Oct;17(10):1198-205
11145224
J Neurochem. 2002 Oct;83(1):57-66
12358729
J Biol Chem. 1986 May 15;261(14):6536-41
3700406
J Cereb Blood Flow Metab. 2003 Apr;23(4):432-40
12679720
J Neurochem. 2004 Aug;90(3):526-36
15255930
J Neurochem. 2001 Oct;79(1):110-8
11595763
J Neurochem. 1999 Sep;73(3):1206-11
10461913
J Histochem Cytochem. 1999 Oct;47(10):1255-64
10490454
Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8850-5
11438712
Cell. 1994 May 20;77(4):491-502
7910522
J Biol Chem. 1999 May 7;274(19):13675-80
10224140
Eur J Pharm Sci. 2001 Jan;12(3):215-22
11113640